Elia Sechi1, Eslam Shosha1, Jonathan P Williams1, Sean J Pittock1, Brian G Weinshenker1, B Mark Keegan1, Nicholas L Zalewski1, Alfonso Sebastian Lopez-Chiriboga1, Jiraporn Jitprapaikulsan1, Eoin P Flanagan2. 1. From the Departments of Neurology (E.S., E.S., S.J.P., B.G.W., B.M.K., N.L.Z., A.S.L.-C., E.P.F.), Health Sciences Research (J.P.W.), and Laboratory Medicine and Pathology (S.J.P., J.J., E.P.F.), Mayo Clinic College of Medicine, Rochester, MN. 2. From the Departments of Neurology (E.S., E.S., S.J.P., B.G.W., B.M.K., N.L.Z., A.S.L.-C., E.P.F.), Health Sciences Research (J.P.W.), and Laboratory Medicine and Pathology (S.J.P., J.J., E.P.F.), Mayo Clinic College of Medicine, Rochester, MN. flanagan.eoin@mayo.edu.
Abstract
OBJECTIVE: Diagnostic criteria from 2002 classify transverse myelitis (TM) as idiopathic or disease associated but predate the discovery of aquaporin-4 (AQP4)-immunoglobulin G (IgG) and myelin oligodendrocyte glycoprotein (MOG)-IgG, which associate with TM. Prior incidence estimates of idiopathic TM (ITM) range from 1 to 6.2 per 1 million. We sought to determine whether the population-based incidence and prevalence of ITM were reduced by testing patients with ITM for AQP4/MOG-IgG and reclassifying seropositive cases as having disease-associated TM. METHODS: For this observational study, we retrospectively identified all cases of incident (January 1, 2003-December 31, 2016) and prevalent (December 31, 2016) ITM in Olmsted County (85% white) by using the Rochester Epidemiology Project medical records linkage system. ITM was defined by the 2002 Transverse MyelitisConsortium Working Group diagnostic criteria. Available sera were tested for AQP4-IgG and MOG-IgG. RESULTS: Twenty-four patients (incident 22, prevalent 17) initially met 2002 ITM criteria (longitudinally extensive TM [LETM] 6). Sera were tested for AQP4-IgG in 22 of 24 (92%) and MOG-IgG in 21 of 24 (88%). Three seropositive cases (AQP4-IgG 2, MOG-IgG 1) were identified and reclassified as having disease-associated TM, accounting for 14% of total incident and 12% of total prevalent cases. AQP4-IgG and MOG-IgG seropositive cases represented 50% (3 of 6) of idiopathic LETM. After reclassification of seropositive patients, the final ITM incidence was 8.6 per 1,000,000 and prevalence was 7.9 per 100,000. Three cases of ITM (14%) subsequently fulfilled multiple sclerosis criteria within the study period. CONCLUSIONS: The availability of AQP4-IgG and MOG-IgG modestly reduced ITM incidence and prevalence, which remained higher than previously reported in this predominantly white population. Incorporation of these biomarkers into future revisions of TM diagnostic criteria should be considered.
OBJECTIVE: Diagnostic criteria from 2002 classify transverse myelitis (TM) as idiopathic or disease associated but predate the discovery of aquaporin-4 (AQP4)-immunoglobulin G (IgG) and myelin oligodendrocyte glycoprotein (MOG)-IgG, which associate with TM. Prior incidence estimates of idiopathic TM (ITM) range from 1 to 6.2 per 1 million. We sought to determine whether the population-based incidence and prevalence of ITM were reduced by testing patients with ITM for AQP4/MOG-IgG and reclassifying seropositive cases as having disease-associated TM. METHODS: For this observational study, we retrospectively identified all cases of incident (January 1, 2003-December 31, 2016) and prevalent (December 31, 2016) ITM in Olmsted County (85% white) by using the Rochester Epidemiology Project medical records linkage system. ITM was defined by the 2002 Transverse MyelitisConsortium Working Group diagnostic criteria. Available sera were tested for AQP4-IgG and MOG-IgG. RESULTS: Twenty-four patients (incident 22, prevalent 17) initially met 2002 ITM criteria (longitudinally extensive TM [LETM] 6). Sera were tested for AQP4-IgG in 22 of 24 (92%) and MOG-IgG in 21 of 24 (88%). Three seropositive cases (AQP4-IgG 2, MOG-IgG 1) were identified and reclassified as having disease-associated TM, accounting for 14% of total incident and 12% of total prevalent cases. AQP4-IgG and MOG-IgG seropositive cases represented 50% (3 of 6) of idiopathic LETM. After reclassification of seropositive patients, the final ITM incidence was 8.6 per 1,000,000 and prevalence was 7.9 per 100,000. Three cases of ITM (14%) subsequently fulfilled multiple sclerosis criteria within the study period. CONCLUSIONS: The availability of AQP4-IgG and MOG-IgG modestly reduced ITM incidence and prevalence, which remained higher than previously reported in this predominantly white population. Incorporation of these biomarkers into future revisions of TM diagnostic criteria should be considered.
Authors: Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen Journal: Lancet Neurol Date: 2017-12-21 Impact factor: 44.182
Authors: Eoin P Flanagan; Philippe Cabre; Brian G Weinshenker; Jennifer St Sauver; Debra J Jacobson; Masoud Majed; Vanda A Lennon; Claudia F Lucchinetti; Andrew McKeon; Marcelo Matiello; Nilifur Kale; Dean M Wingerchuk; Jay Mandrekar; Jessica A Sagen; James P Fryer; Angala Borders Robinson; Sean J Pittock Journal: Ann Neurol Date: 2016-04-04 Impact factor: 10.422
Authors: A Sebastian López-Chiriboga; Masoud Majed; James Fryer; Divyanshu Dubey; Andrew McKeon; Eoin P Flanagan; Jiraporn Jitprapaikulsan; Naga Kothapalli; Jan-Mendelt Tillema; John Chen; Brian Weinshenker; Dean Wingerchuk; Jessica Sagen; Avi Gadoth; Vanda A Lennon; B Mark Keegan; Claudia Lucchinetti; Sean J Pittock Journal: JAMA Neurol Date: 2018-11-01 Impact factor: 18.302
Authors: Elia Sechi; Karl N Krecke; Sean J Pittock; Divyanshu Dubey; A Sebastian Lopez-Chiriboga; Amy Kunchok; Brian G Weinshenker; Nicholas L Zalewski; Eoin P Flanagan Journal: Mult Scler Date: 2020-02-27 Impact factor: 6.312
Authors: Elia Sechi; Laura Cacciaguerra; John J Chen; Sara Mariotto; Giulia Fadda; Alessandro Dinoto; A Sebastian Lopez-Chiriboga; Sean J Pittock; Eoin P Flanagan Journal: Front Neurol Date: 2022-06-17 Impact factor: 4.086
Authors: Justin R Abbatemarco; Jonathan R Galli; Michael L Sweeney; Noel G Carlson; Verena C Samara; Haley Davis; Stefanie Rodenbeck; Ka-Ho Wong; M Mateo Paz Soldan; John E Greenlee; John W Rose; Alen Delic; Stacey L Clardy Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-08-31